在肌缩侧面硬化症 (ALS) 中药物重定向
Emily Carroll1,2, Jakub Scaber1,2, Kilian V M Huber3,4
1Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Expert opinion on drug discovery
|March 3, 2025
概括
药物再利用提供了一个有希望的策略,通过重新评估现有药物来寻找新的肌缩侧面硬化症 (ALS) 治疗方法. 这种方法可以克服ALS传统药物发现的挑战,改善患者的选择.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 针对肌缩性侧面硬化症 (ALS) 的药物发现面临重大挑战,传统方法取得的成功有限.
- 将现有的,经过临床批准的药物重新用于新的适应症是一个可行的替代策略.
研究的目的:
- 审查ALS药物发现方面的挑战.
- 检查药物重新利用的潜力,以确定新的ALS治疗方法.
- 概述临床前和临床研究的原则,以弥合翻译差距.
主要方法:
- 对原始出版物,新闻稿和临床试验的文献评论.
- 在实验模型和计算方法中讨论选方法.
- 考虑临床前和临床研究的一般原则.
主要成果:
- 药物重新定位对ALS的新药发现具有战略优势.
- 可以使用一系列的选和计算方法.
- 弥合翻译差距需要仔细的临床前和临床研究设计.
结论:
- 药物重定向具有显著的潜力,可以增强ALS患者的治疗选择.
- 严格的临床前研究对于识别有前途的化合物至关重要.
- 学术界,行业和利益相关者之间的协作努力对于重新定位疗法的成功临床转化至关重要.
更多相关视频
相关概念视频
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...